This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF
catalog :
193-BC
quantity :
50 ug
price :
339 USD
citations: 3
Reference
Nanna A, Kel In A, Theile C, Pierson J, Voo Z, Garg A, et al. Generation and validation of structurally defined antibody-siRNA conjugates. Nucleic Acids Res. 2020;48:5281-5293 pubmed publisher
Bu D, Singh R, Choi E, Ruella M, Nunez Cruz S, Mansfield K, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9:25764-25780 pubmed publisher
Isik G, Sliepen K, van Montfort T, Sanders R. Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PLoS ONE. 2014;9:e107683 pubmed publisher
product information
brand :
R&D Systems
master code :
193-BC
SKU :
193-BC-050
product name :
Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF
description :
The Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human BCMA/TNFRSF17 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
BCMA/TNFRSF17
category :
Proteins and Enzymes
unit size :
50 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
35-45 kDa, reducing conditions
theoretical molecular weight :
32 kDa (monomer)
gene symbol :
TNFRSF17
details of functionality :
Measured by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated mouse B cells. Moore, P.A. et al . (1999) Science 285 :260; Gross, J.A. et al . (2000) Nature 404 :995; Schneider, P. et al . (1999) J. Exp. Med. 189 :1747. The ED50 for this effect is 0.01-0.04 µg/mL in the presence of 100 ng/mL of rhAPRIL.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
catalog number base :
193-BC
accessionNumbers :
Q6PE46
applications :
Bioactivity
source :
Mouse myeloma cell line, NS0-derived human BCMA/TNFRSF17 protein Human BCMA (Met1-Ala54) Accession # Q6PE46 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
2020 USD :
339
2021 USD :
339 USD
alt names :
B cell maturation antigen, B-cell maturation protein, BCMAtumor necrosis factor receptor superfamily member 17, BCMB-cell maturation factor, CD269, CD269 antigen, TNFRSF13A, TNFRSF17, tumor necrosis factor receptor superfamily, member 17
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.